Synergistic and antagonistic drug combinations against SARS-CoV-2; QSAR modeling of SARS‐CoV Mpro inhibitors identifies Sufugolix, Cenicriviroc, Proglumetacin and other drugs as candidates for repurposing against SARS‐CoV‐2; Learning from history: do not flatten the curve of antiviral research!; COVID-KOP: integrating emerging COVID-19 data with the ROBOKOP database; Conserved coronavirus proteins as targets of broad-spectrum antivirals; COVID-19 Knowledge Extractor (COKE): A Curated Repository of Drug–Target Associations Extracted from the CORD-19 Corpus of Scientific Publications on COVID-19; ZINC Express: a virtual assistant for purchasing compounds annotated in the zinc database; Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single-cell RNA sequencing; Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents; Praemonitus praemunitus: can we forecast and prepare for future viral disease outbreaks?; Sequence and structure conservation analysis of the key coronavirus proteins supports the feasibility of discovering broad-spectrum antiviral medications.; Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents (preprint)
